GlucoTrack

GlucoTrack Receivables

Accounts Receivable of GlucoTrack (GCTK) as of Oct 28, 2026.

Receivables

0.00USD

Last updated:

Accounts Receivable of GlucoTrack is 2021 0.00 USD. Accounts Receivable of GlucoTrack was 2020 66,000.00 USD. It decreases by % lower compared to the previous year.

The GlucoTrack Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2014
23,000.00 USD
Jan 1, 2015
18,000.00 USD
Jan 1, 2016
92,000.00 USD
Jan 1, 2017
122,000.00 USD
Jan 1, 2018
23,000.00 USD
Jan 1, 2019
70,000.00 USD
Jan 1, 2020
66,000.00 USD
Jan 1, 2021
0.00 USD
The GlucoTrack Receivables history
YEARReceivablesYoY
0.00USD-100.00%
66,000.00USD-5.71%
70,000.00USD+204.35%
23,000.00USD-81.15%
122,000.00USD+32.61%
92,000.00USD+411.11%
18,000.00USD-21.74%
23,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlucoTrack Stock analysis

What does GlucoTrack do? GlucoTrack, Inc. makes money by selling non-invasive glucose monitoring devices and related software solutions to people with diabetes and pre-diabetes. The company's GlucoTrack device provides glucose level readings without finger sticks, targeting Type II diabetes and prediabetes users. It also develops an implantable continuous glucose monitor for Type I diabetes and insulin-dependent Type II diabetes patients. The firm offers companion applications and cloud-based solutions to deliver real-time, data-driven tools for diabetes management. Its primary customers are individuals managing diabetes through non-invasive monitoring solutions, with a focus on Type II diabetes and pre-diabetes segments. GlucoTrack, Inc. generates revenue through the commercialization of its non-invasive glucose monitor and the development of its implantable continuous glucose monitor. The company's products are designed for specific diabetes segments: Type II diabetes and prediabetes users for the GlucoTrack device, and Type I diabetes and insulin-dependent Type II diabetes patients for the implantable monitor. The firm's cloud-based platform and companion apps are integral to its service offering, providing personalized diabetes management tools. Revenue streams include device sales and software services for these targeted user groups. The company's business model centers on direct sales of its GlucoTrack device and implantable monitor to diabetes patients. It focuses on Type II diabetes and prediabetes for the non-invasive monitor, while the implantable version targets Type I diabetes and insulin-dependent Type II diabetes. The firm's cloud-based solutions and companion applications are sold as part of the overall diabetes management platform. Revenue is derived from both hardware sales and subscription-based software services for these specific patient segments. GlucoTrack is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlucoTrack stock

On Eulerpool you can find the complete historical development of Accounts Receivable GlucoTrack since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's GlucoTrack historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GlucoTrack

All Key Metrics — GlucoTrack